As most cancer patients are seen in the community setting, community oncologists will play an instrumental role in patient referral and likely determine the initial adoption of CAR-T therapies.
The shift from fee-for-service to value-based payment systems is likely to continue.
The way in which health care is delivered must be rethought with a focus on care coordination, patient engagement, and specific treatments through clinical pathways.
Authors present findings on the limited knowledge and misconceptions of health care providers regarding patient-centered medicine and patient-reported outcomes.
Dr Stepanski adds to the discussion on patient-reported outcomes in oncology with a counterpoint on the recent progress of these measures in trials and care settings.
George Dahlman responds to a viewpoint on chemotherapy drug shortages by detailing policy measures that have been put in place to help address this issue.
ASCO Policy Statement on Clinical Pathways in Oncology Represents Great Progress for Clinical Pathways
Winston Wong, PharmD, explains how the recent policy statement released by the American Society of Clinical Oncology represents a significant step forward for clinical pathways as a whole.
Before the relative value of a drug can be determined, one must first consider how value is defined by the patient. Dr. Benson and Ms. McClure respond to a viewpoint by Roger Longman, MA.
Dr. David R. Henderson and Charle L. Hooper offer another perspective on healthcare reform.